The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Some might describe Johnson & Johnson's business as boring, but sometimes, that's not such a bad thing. Selling pharmaceutical products is a steady and reliable business even when the economy is ...